Shah Wealth Advisors LLC Makes New Investment in Novartis AG $NVS

Shah Wealth Advisors LLC acquired a new stake in Novartis AG (NYSE:NVS) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 4,346 shares of the company’s stock, valued at approximately $681,000.

Other hedge funds also recently modified their holdings of the company. Highland Investment Advisors LLC acquired a new position in Novartis in the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. boosted its holdings in shares of Novartis by 552.0% during the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after acquiring an additional 138 shares during the period. Atlatl Advisers LLC bought a new stake in shares of Novartis during the second quarter worth approximately $26,000. Archer Investment Corp grew its position in shares of Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the last quarter. Finally, CrossGen Wealth LLC bought a new position in shares of Novartis during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NVS shares. Citigroup restated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Stock Performance

NYSE:NVS opened at $159.95 on Friday. The company has a market cap of $305.21 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 3.18 and a beta of 0.45. Novartis AG has a fifty-two week low of $121.57 and a fifty-two week high of $170.46. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The stock has a fifty day moving average price of $155.74 and a 200-day moving average price of $153.78.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. As a group, equities analysts anticipate that Novartis AG will post 8.84 EPS for the current fiscal year.

Novartis News Summary

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported that remibrutinib met the primary endpoint in two Phase 3 trials for relapsing multiple sclerosis. The result supports the potential expansion of the drug beyond its existing development opportunities. Novartis Remibrutinib Phase 3 Trial Results
• Neutral Sentiment: Novartis’ recent Basel-related move and a reported multibillion-dollar investment to improve how an existing medicine is delivered point to a shift in strategic priorities. The initiative could support product differentiation and lifecycle management, although its financial impact is not yet clear. Novartis Basel Strategic Move
• Neutral Sentiment: Options traders purchased a large volume of Novartis put contracts, signaling increased near-term hedging or bearish speculation. This reflects market sentiment rather than a change in the company’s fundamentals. Novartis Put Option Activity
• Negative Sentiment: Novartis and partner Ionis Pharmaceuticals said pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial. The setback weakens the outlook for a closely watched treatment targeting lipoprotein(a), a major potential growth opportunity in cardiovascular medicine. Pelacarsen Late-Stage Trial Failure
• Negative Sentiment: Novartis paused eight experimental rap-cel CAR-T trials after three patient deaths linked to severe immune reactions. The safety issue threatens development of the company’s autoimmune and neurological cell-therapy programs and raises regulatory and disclosure concerns. Novartis CAR-T Trial Halt
• Negative Sentiment: Erste Group Bank lowered its earnings estimates for Novartis, adding pressure to expectations for future results. Combined with the pelacarsen failure and CAR-T safety pause, the revisions reinforce concerns about pipeline execution. Erste Group Cuts Novartis Earnings Estimates

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.